Viking Therapeutics Aktie
WKN DE: A12GD6 / ISIN: US92686J1060
|
24.09.2026 17:30:33
|
Here's Why Viking Therapeutics Shares Slumped Today
Viking Therapeutics (NASDAQ: VKTX) stock declined by 14.5% in early morning trading today, a week after the company reported top-line results from a maintenance study of its key weight-loss drug, VK2735. However, don't panic. Today's move is not directly related to the results released a couple of days ago.
In fact, the results were positive enough to prompt management to announce an offering of common stock and convertible senior notes to capitalize on the share price surge and raise capital to fund its ongoing development pipeline, including VK2735 in Phase 3 trials.
Management announced a $200 million offering of common stock and $200 million in convertible senior notes due in 2023 on Wednesday. These offerings were clearly well received because today management announced it had upsized the offering to 7,857,143 shares of common stock at $35 (equivalent to about $275 million) and $225 million in convertible senior notes.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Viking Therapeutics Inc
|
27.10.26 |
Ausblick: Viking Therapeutics veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net) | |
|
28.07.26 |
Ausblick: Viking Therapeutics stellt Quartalsergebnis zum abgelaufenen Jahresviertel vor (finanzen.net) |
Analysen zu Viking Therapeutics Inc
Aktien in diesem Artikel
| Viking Holdings Ltd Registered Shs | 95,00 | -5,35% |
|
| Viking Therapeutics Inc | 23,55 | -1,46% |
|